Anzeige
Mehr »
Mittwoch, 20.05.2026 - Börsentäglich über 12.000 News
Bewertet mit 8$ - Preis:139$: Peer-Übernahmen brachten Anlegern dreistellige Gewinne
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PEFW | ISIN: KYG2588M1006 | Ticker-Symbol: PH4
Tradegate
19.05.26 | 13:06
0,811 Euro
-2,10 % -0,017
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
CSTONE PHARMACEUTICALS CO LTD Chart 1 Jahr
5-Tage-Chart
CSTONE PHARMACEUTICALS CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,8280,87414:29
0,8320,87414:31

Aktuelle News zur CSTONE PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoCSTONE PHARMA-B Plans to Repurchase Up to 136 Million Shares on Open Market6
13.05.CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - ON-MARKET SHARE REPURCHASE-
11.05.CSTONE PHARMA-B Launches Nationwide Commercial Shipment of Locally Manufactured Pralsetinib Capsules3
11.05.CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - CSTONE INITIATES NATIONWIDE COMMERCIAL SUPPLY OF LOCALLY MANUFACTURED PRALSETINIB CAPSULES6
27.04.CSTONE PHARMA-B (02616): ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 20253
27.04.CSTONE PHARMA-B (02616): 2025 ANNUAL REPORT-
CSTONE PHARMACEUTICALS Aktie jetzt für 0€ handeln
22.04.CSTONE PHARMA-B (02616): COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE1
22.04.CSTONE PHARMA-B (02616): NEXT DAY DISCLOSURE RETURN1
22.04.CStone Pharmaceuticals to Announce Multiple Key Clinical Updates of CS2009 at ASCO Annual Meeting in US2
22.04.CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - ASCO 2026 PREVIEW: CSTONE TO PRESENT UPDATED CLINICAL DATA FOR CS2009 (PD 1/VEGF/CTLA 4 TRISPECIFIC ...3
20.04.CStone stellt neue ADC-Daten auf AACR-Jahrestagung vor: Aktie im Höhenflug6
20.04.CStone Pharmaceuticals Presents Clinical Research Results of Three In-house Pipelines at AACR Annual Meeting in the US5
20.04.CStone presents preclinical data on three ADC candidates at AACR1
20.04.CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - CSTONE PRESENTED PRECLINICAL DATA FOR THREE NOVEL OR DIFFERENTIATED ADCS AT AACR 2026, INCLUDING CS5007 ...1
15.04.CSTONE PHARMA-B (02616): PLACING OF NEW SHARES UNDER GENERAL MANDATE2
02.04.CSTONE PHARMA-B (02616): LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS4
02.04.CSTONE PHARMA-B (02616): LETTER AND REPLY FORM TO NON-REGISTERED SHAREHOLDERS - ARRANGEMENT OF ELECTRONIC DISSEMINATION OF CORPORATE COMMUNICATIONS2
26.03.CSTONE PHARMA-B (02616): ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 20255
26.03.CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - CSTONE UPDATED CLINICAL PROGRESS AND KEY PHASE I/II DATA FOR CS2009 (PD-1/VEGF/CTLA-4 TRISPECIFIC ANTIBODY)2
25.03.CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - SUGEMALIMAB RECEIVES [I, A] RECOMMENDATION IN ESMO GUIDELINE FOR CONSOLIDATION THERAPY IN PATIENTS WITH ...3
Weiter >>
33 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1